Combining Chidamide and Venetoclax for Hard-to-Treat Acute Promyelocytic Leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of a combination therapy using chidamide, a histone deacetylase inhibitor, and venetoclax in patients with acute promyelocytic leukemia (APL) who have become resistant to standard treatments with retinoic acid and arsenic. The study aims to assess how well this new approach can induce differentiation and apoptosis in resistant APL cells. It is a multi-center prospective study that builds on promising pre-clinical findings indicating that targeting HDAC3 can degrade the oncoprotein responsible for the disease. Participants will be monitored for treatment efficacy and feasibility.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with PML-RARα+ APL
* Patients in non-remission status after treatment of RA combined with As
* Patients with life expectance \>=3 months
* Inform consent provided

Exclusion Criteria:

* Patients with incontrollable infection
* Patients with life-expectancy less than 2 months
* Patients with abnormal liver (\>3XN) and renal function (\>3XN）

Where it's running

• Jiong HU
  Shanghai, Shanghai Municipality, China Recruiting
• NanFang Hospital
  Guangzhou, China Recruiting
• The Affiliated Huai An No 1 Perople's Hospital of NanJing University
  Huai'an, Jiangsu, China Not yet recruiting
• The First Affiliated Hospital of Nanchang University
  Nanchang, Jiangxi, China Not yet recruiting
• Zhaxin Hospital, Go Broad Health Care
  Shanghai, Shanghai Municipality, China Active not recruiting

Study contacts

• Study coordinator: Chun Wang, M.D.,
• Email: wangchunsh@medmail.com.cn
• Phone: 8613386259777

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early use of oral Realgar-Indigo Naturalis plus all-trans retinoic acid for acute promyelocytic leukemia

  This study will test whether starting an oral arsenic medicine called Realgar-Indigo Naturalis Formula (RIF) together with all-trans retinoic acid (ATRA) early in treatment can lower early deaths in adults with acute promyelocytic leukemia (APL).

  Recruiting Phase 3 First Affiliated Hospital Xi'an Jiaotong University · Xi'an, Shaanxi · NCT07503730

• QTX-2101 (oral arsenic) plus ATRA for adults with low- or intermediate-risk APL

  This Phase 3 trial tests whether an oral arsenic capsule (QTX-2101) combined with ATRA works well and is safe for adults aged 18–70 with newly diagnosed low- or intermediate-risk acute promyelocytic leukemia.

  Recruiting at 36 sites Phase 3 Quetzal Therapeutics · Birmingham, Alabama and 35 other locations · NCT07504458

• Combining oral arsenic and ATRA for treating newly diagnosed acute promyelocytic leukemia

  This study is testing if a new treatment combining oral arsenic and ATRA can help newly diagnosed patients with acute promyelocytic leukemia live longer and feel better, especially those at high risk.

  Recruiting Phase 2 Instituto do Cancer do Estado de São Paulo · São Paulo, São Paulo · NCT06982274

• Using sirolimus to treat thrombocytopenia related to antiphospholipid antibodies

  This study is testing if the medication sirolimus can help people with low platelet counts caused by antiphospholipid antibodies feel better compared to those who receive a placebo.

  Recruiting at 10 sites Phase 4 Peking University First Hospital · Changsha, Hunan and 9 other locations · NCT06722586

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.